Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass

Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial

“…Many in vivo preclinical studies of autoimmune inflammatory arthritis have demonstrated that, despite causing transient increases in proinflammatory cytokines, such as TNF-α, IL-6 and IL-1β,26 zoledronate has a beneficial effect on development of bone erosion and bone marrow oedema (BMO) 7–9 27. In a study of 39 people with early RA on methotrexate, treatment with zoledronate reduced development of new erosions and BMO on MRI over 26 weeks 10.…”

Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers

“…A similar conclusion can be extracted from the indirect comparison of BMD changes in treatment-naïve [10] and pre-treated with alendronate [7] patients receiving denosumab in other studies. Thus, switching from zoledronic acid to denosumab could represent an effective modality, especially in patients with impaired renal function [11] or patients reluctant to continue treatment with zoledronic acid due to an adverse event, most commonly experience of an acute phase reaction following the initial infusion [12]. As expected, denosumab significantly decreased bone formation and resorption markers in both groups.…”

The role of cytokines and adipocytokines in zoledronate‐induced acute phase reaction in postmenopausal women with low bone mass

“…This was an additional retrospective analysis based on frozen samples from a previous, prospectively designed, open label, interventional study. Caucasian postmenopausal women with low bone mass (bone mineral density T ‐score of ≤−2·0 at the lumbar spine and/or the femoral neck) assigned to zoledronate 5 mg had been recruited from the outpatient clinics of the Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece for the needs of our recently published study . For the purposes of the present study, we conducted additional measurements of various adipocytokines in stored serum samples.…”

“…White blood cell count, white blood cell type and C‐reactive protein had been measured within 1 h. Additional samples had been centrifuged immediately and serum had been separated and stored at −30 °C. Serum total calcium, phosphate, creatinine, total alkaline phosphatase, interleukin‐6 and tumour necrosis factor‐alpha had already been measured for the needs of the previous study . Additional measurements included serum glucose, insulin, visfatin, resistin and leptin.…”

“…We have recently reported that pretreatment higher lymphocyte number increases the risk of APR . We aimed to further investigate various cytokines and adipocytokines as potential risk factors for the development of zoledronate‐induced APR and to develop a prognostic model for its prediction.…”